Clinical TrialsAnixa Biosciences has initiated the transfer of the Investigational New Drug (IND) application to support the upcoming Phase 2 trial of its breast cancer vaccine, following positive preliminary results from the Phase 1 trial.
FundingWith $17.3M in cash, and a low burn rate, Anixa should have runway into FY27 and through key events generated by its partnerships to unlock investor value.
Intellectual PropertyThe United States Patent and Trademark Office is set to issue a patent that covers Anixa Biosciences' breast cancer vaccine technology, extending intellectual property protection into the mid-2040s.
PartnershipsAnixa's strategic partnerships with leading cancer centers like Cleveland Clinic and Moffitt Cancer Center both validate its programs and ensures efficient capital use while the programs work toward generating clinical proof of concept which should pave the way to later-stage studies.